OSE Immunotherapeutics SA
PAR:OSE

Watchlist Manager
OSE Immunotherapeutics SA Logo
OSE Immunotherapeutics SA
PAR:OSE
Watchlist
Price: 5.9 EUR -4.07% Market Closed
Market Cap: 129.4m EUR

OSE Immunotherapeutics SA
Tax Provision

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

OSE Immunotherapeutics SA
Tax Provision Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Tax Provision CAGR 3Y CAGR 5Y CAGR 10Y
OSE Immunotherapeutics SA
PAR:OSE
Tax Provision
-€3.4m
CAGR 3-Years
-44%
CAGR 5-Years
-18%
CAGR 10-Years
N/A
Valneva SE
PAR:VLA
Tax Provision
-€761k
CAGR 3-Years
40%
CAGR 5-Years
3%
CAGR 10-Years
-9%
Nanobiotix SA
PAR:NANO
Tax Provision
-€261k
CAGR 3-Years
-197%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
G
Genfit SA
PAR:GNFT
Tax Provision
-€5k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Inventiva SA
PAR:IVA
Tax Provision
-€733k
CAGR 3-Years
-27%
CAGR 5-Years
-21%
CAGR 10-Years
N/A
Eurobio Scientific SA
PAR:ALERS
Tax Provision
-€3.3m
CAGR 3-Years
47%
CAGR 5-Years
-46%
CAGR 10-Years
N/A

OSE Immunotherapeutics SA
Glance View

Market Cap
128.4m EUR
Industry
Biotechnology

OSE Immunotherapeutics SA develops immunotherapy products for cancer and auto-immune disease. The company is headquartered in Nantes, Pays De La Loire and currently employs 61 full-time employees. The company went IPO on 2015-03-30. The company develops immunotherapies, directly or through partnerships, for the activation and regulation of the immune system in immuno-oncology and in autoimmune diseases. The firm's research and development in immunology is based on 3 platforms, such as T cell-based vaccines, Immuno-Oncology (myeloid targets) and Auto-Immunity & Inflammation. The company provides technological and scientific platforms: neoepitopes, agonist or antagonist monoclonal antibodies, ideally positioned to fight cancer and autoimmune diseases.

OSE Intrinsic Value
7.94 EUR
Undervaluation 26%
Intrinsic Value
Price

See Also

What is OSE Immunotherapeutics SA's Tax Provision?
Tax Provision
-3.4m EUR

Based on the financial report for Jun 30, 2024, OSE Immunotherapeutics SA's Tax Provision amounts to -3.4m EUR.

What is OSE Immunotherapeutics SA's Tax Provision growth rate?
Tax Provision CAGR 5Y
-18%

The average annual Tax Provision growth rates for OSE Immunotherapeutics SA have been -44% over the past three years , -18% over the past five years .

Back to Top